Viking Therapeutics Inc
NASDAQ:VKTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.72
94.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Viking Therapeutics Inc
Viking Therapeutics Inc
Revenue
Viking Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Viking Therapeutics Inc
Glance View
Viking Therapeutics Inc. is an innovative biotechnology company dedicated to developing novel therapies for metabolic and endocrine disorders. With a strong focus on identifying and advancing unique drug candidates, Viking has carved a niche for itself in the competitive biopharmaceutical landscape. The company’s lead programs revolve around selective androgen receptor modulators (SARMs) and therapies aimed at improving insulin sensitivity and metabolism. By leveraging cutting-edge science and a team of experienced professionals, Viking aspires to offer transformative treatments for conditions such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), both of which present significant unmet medical needs in the healthcare market today. Investors are drawn to Viking Therapeutics not only for its promising drug pipeline but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company operates with a clear vision: to turn scientific innovation into viable treatments that improve patients' lives. As it advances its lead candidates through clinical trials and potentially toward the commercialization phase, Viking presents an intriguing opportunity for investors looking to engage with a company at the forefront of metabolic disease treatment. With a focus on best practices, rigorous clinical evaluation, and an eye on potential regulatory pathways, Viking Therapeutics is well-positioned to make a significant impact in the biotechnology field, all while offering the potential for substantial returns to its stakeholders.
See Also
What is Viking Therapeutics Inc's Revenue?
Revenue
0
USD
Based on the financial report for Sep 30, 2024, Viking Therapeutics Inc's Revenue amounts to 0 USD.
You don't have any saved screeners yet
